Inflammatory bowel disease (IBD) refers a group of chronic inflammatory disease affecting the intestines; namely, ulcerative colitis (UC) and Crohn s disease (CD). IBD affects between 2.4 and 3.1 million adults in the United States, conferring substantial disease burden. Despite therapeutic advancements, a significant proportion of patients with IBD do not achieve optimal clinical outcomes with current therapies., so they can better understand the rationale behind investigational therapies. Precision medicine, distinct from personalized medicine, leverages specific clinical biomarkers and assessment tools to tailor treatment plans for individual patients, aiming for more effective management of IBD. As research on these emerging targets advances, it will be essential that HCPs understand the pathophysiology of IBD and how each of these signaling complexes work to perpetuate inflammation and disease symptomology. In this first installment of a CMEO podcast series expert faculty will discuss strategies to identify new and emerging pathological targets, evaluate new and emerging evidence related to these novel targets, and the importance of these targets in treatment decision-making.
- Provider:CME Outfitters, LLC
- Activity Link: https://www.cmeoutfitters.com
- Start Date: 2025-01-31 06:00:00
- End Date: 2025-01-31 06:00:00
- Credit Details: AAPA Category 1 Credit™️: 0.5 hours
AMA PRA Category 1 Credit™️: 0.5 hours
Nursing: 0.5 hours
Pharmacy: 0.5 hours - MOC Credit Details: ABIM - 0.5 Point; Credit Type(s): Medical Knowledge (ABIM)
- Commercial Support: Source: Merck (Any division) - Amount: 0 - Is Kind Support: False
- Activity Type: Enduring Material
- CME Finder Type: Online Learning
- Fee to Participate: No, it's free
- Measured Outcome: Learner/Team Competence
- Provider Ship: Directly Provided
- Registration: Open to all
- Specialty: Gastroenterology, Internal Medicine